Prescribing Entyvio

Prescribing Entyvio

Entyvio is given by intravenous infusion every 8 weeks after an initial induction phase. Treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn’s disease.1

LEARN MORE

Why prescribe Entyvio?

Why prescribe Entyvio?

The safety and efficacy of Entyvio is supported by the results of the GEMINI™ Studies.1-4 These four phase III studies involved 2,400 individuals with UC or CD who were recruited from nearly 40 countries. GEMINI is the largest phase III clinical trial programme to date that evaluated a new treatment for UC or CD concurrently.

LEARN MORE

About Takeda

Takeda

Takeda Pharmaceutical Company Limited has a long history in the research and development, manufacturing, sales and marketing, and import/export of pharmaceutical products. The corporate mission to “strive towards better health for people worldwide through leading innovation in medicine” has led to the development of several state-of-the-art medicines, including Entyvio for UC and CD.

LEARN MORE

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Any adverse events observed following the prescription of Entyvio should be reported. In the United Kingdom, adverse event reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.